1. Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis.
- Author
-
Wang X, Cai B, Yang X, Sonubi OO, Zheng Z, Ramakrishnan R, Shi H, Valenti L, Pajvani UB, Sandhu J, Infante RE, Radhakrishnan A, Covey DF, Guan KL, Buck J, Levin LR, Tontonoz P, Schwabe RF, and Tabas I
- Subjects
- Animals, Cells, Cultured, Humans, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Transcriptional Coactivator with PDZ-Binding Motif Proteins, Adaptor Proteins, Signal Transducing metabolism, Cholesterol metabolism, Hepatocytes metabolism, Intracellular Signaling Peptides and Proteins metabolism, Non-alcoholic Fatty Liver Disease metabolism
- Abstract
Incomplete understanding of how hepatosteatosis transitions to fibrotic non-alcoholic steatohepatitis (NASH) has limited therapeutic options. Two molecules that are elevated in hepatocytes in human NASH liver are cholesterol, whose mechanistic link to NASH remains incompletely understood, and TAZ, a transcriptional regulator that promotes fibrosis but whose mechanism of increase in NASH is unknown. We now show that increased hepatocyte cholesterol upregulates TAZ and promotes fibrotic NASH. ASTER-B/C-mediated internalization of plasma membrane cholesterol activates soluble adenylyl cyclase (sAC; ADCY10), triggering a calcium-RhoA-mediated pathway that suppresses β-TrCP/proteasome-mediated TAZ degradation. In mice fed with a cholesterol-rich NASH-inducing diet, hepatocyte-specific silencing of ASTER-B/C, sAC, or RhoA decreased TAZ and ameliorated fibrotic NASH. The cholesterol-TAZ pathway is present in primary human hepatocytes, and associations among liver cholesterol, TAZ, and RhoA in human NASH liver are consistent with the pathway. Thus, hepatocyte cholesterol contributes to fibrotic NASH by increasing TAZ, suggesting new targets for therapeutic intervention., Competing Interests: Declaration of Interests J.B. and L.R.L. own equity interest in CEP Biotech, which has licensed commercialization of a panel of monoclonal antibodies directed against sAC. I.T. and X.W. are co-inventors of a patent application related to the topic of this study, and I.T. is a scientific consultant for Genevant, which is developing therapies for NASH., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF